ArticleAustin journal of drug abuse and addiction2016
Self-reported Sleep Improvement in Buprenorphine MAT (Medication Assisted Treatment) Population.
Article in Austin journal of drug abuse and addiction, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Sleep Health Among Adults in Outpatient Opioid Use Disorder Treatment: A Systematic Review.Journal of psychosocial nursing and mental health services · 2024Pooled it
- Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up Study.JAMA psychiatry · 2019Trial
- Retention Challenges in Opioid Use Disorder Treatment: The Role of Comorbid Psychological Conditions.The western journal of emergency medicine · 2025Article
- Treatment of insomnia associated with alcohol and opioid use: a narrative review.Sleep and biological rhythms · 2024Review
- "It's all connected:" A mixed methods study of insomnia, stigma, and discrimination among individuals on medication for opioid use disorder.Sleep health · 2024Article
- Are we ready to manage an opioid epidemic in the intensive care unit?Anaesthesiology intensive therapy · 2022Review
- Sleep and substance use disorder treatment: A preliminary study of subjective and objective assessment of sleep during an intensive outpatient program.The American journal on addictions · 2021Article
- At the intersection of sleep deficiency and opioid use: mechanisms and therapeutic opportunities.Translational research : the journal of laboratory and clinical medicine · 2021Review
- A review of sleep disturbance in adults prescribed medications for opioid use disorder: potential treatment targets for a highly prevalent, chronic problem.Sleep medicine · 2021Review
- Longitudinal assessment of mental health and well-being in patients being treated with medications for opioid use disorder in primary care.Addictive behaviors reports · 2021Article
- Long-term treatment retention in West Virginia's comprehensive opioid addiction treatment (COAT) program.Journal of the neurological sciences · 2020Review
- Multimodal assessment of sleep in men and women during treatment for opioid use disorder.Drug and alcohol dependence · 2020Article
- West Virginia's model of buprenorphine expansion: Preliminary results.Journal of substance abuse treatment · 2020Article
- Sleep Management Among Patients with Substance Use Disorders.The Medical clinics of North America · 2018Review
- Four single nucleotide polymorphisms in genes involved in neuronal signaling are associated with Opioid Use Disorder in West Virginia.Journal of opioid managementArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
This is a prospective, naturalistic study to evaluate patient's report on sleep and depression in early recovery while receiving buprenorphine in Medication Assisted Treatment (MAT). 40 Subjects entering into MAT with buprenorphine/naloxonefor opioid dependence disorder were recruited. No change of concurrent treatment was made. Subjects were administered Sleep Scale from the Medical Outcomes Study (MOS-Sleep), a 5-item Supplemental Sleep Scale (SSS), and the Beck Depression Inventory II (BDI-II). The measures were administered at day 0 (baseline), 30, 60 and 90 days. The result showed that patients reported significant progressive improvements in three MOS-Sleep subscales: sleep disturbance, sleep indices I and II. The mean scores of SLPD4 (Sleep disturbance) at day 0, 30, 60, 90 were 62.4, 53.2, 53.3, and 48.4 respectively (p=0.0029). Similarly, subscores of SLP6 (Sleep Problem Index I) and SLP 9 (Sleep Problem Index II) were also significantly decreased over time (P=0.038 for SLP6 and p=0.007 for SLP9). BDI-II depression scores improved from "Moderate depression" at baseline to "Mild depression". The mean BDI score decreased from 24.2 to 17.0 after 90 days of treatment. Findings suggest that subjects reported improvement in both sleep and depression after initiating MAT with buprenorphine/naloxone.
Indexed as
Identifiers
28133635PMC5270620W2583964025What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.